We report a prototype approach to formulate gold nanoparticlebased X-ray absorbing agents through surface-engineering of a cisplatin pharmacophore with modified polyacrylate. The resulting agents exhibit both chemo-therapeutic potency to cancer cells and Auger-mediated secondary electron emission, showing great potential to improve the therapeutic efficacy of chemo-radiation.
Surface-engineered nanomaterials, and their derivative products, are highly attractive candidates for therapeutic applications. The advantages of using these constructs arise primarily from their nanoscale dimensions and controllable surface chemistry, allowing selective delivery of an incorporated payload to a tumor interstitium via leaky vasculature, while avoiding systemic clearance through renal ltration. The improved therapeutic window and enhanced pharmacokinetic proles, for example, have demonstrated substantial potential for applications in anticancer drugs and tumor imaging agents.
1,2
Among diverse surface-engineered nanomaterials attempted to address nanostructure-biological activity relationships, functionalized gold nanoparticles (AuNPs) are considered one of the most important, 3, 4 primarily due to their intrinsically non-toxic nature, good redox stability, specic surface plasmon resonance (SPR) bands, and facile surface chemistry. As a result, AuNPs have been widely exploited for a variety of biomedical applications including delivery of small-interfering RNA, 5, 6 pharmaceuticals, [7] [8] [9] imaging agents, 10, 11 facilitation of computed tomography, 12 surface-enhanced Raman scattering imaging, and photothermal therapy.
13-15
Using secondary electron emission from AuNPs, 16, 17 recent developments suggest an exciting potential for using AuNPs to enhance the X-ray dosage at the target site in radiation therapy. Based on this concept, the Auger-type electron emission should have the capacity to deliver sufficient doses of highly localized energy to the cellular organelles (e.g., DNA in nuclear chromosomes) and to induce substantial damage to the targeted cells. [18] [19] [20] Furthermore, because of their rapid decay in nanoscale volumes, the linear-energy-transfer properties of Auger electrons may prevent damage to the surrounding healthy tissue. 21 Moreover, the overall therapeutic performance can be further improved conceptually by incorporating intelligent and complementary design principles.
Herein, we demonstrate an approach to develop and combine chemo-and radiation-therapeutic modalities. 31 To this end, our work begins from the foundation of multiple complementary characterization approaches in order to understand the chemical formulation of the drug-tethered nanoplatform, prior to the study of Auger-mediated radiotherapy and in vitro chemotherapeutic efficacy.
Lipoic PAA (M n ¼ 2.4 kDa) was prepared via amide coupling of lipoic acid with poly(tert-butyl acrylate) followed by acidolysis (details in the ESI †). Then, a 4-fold excess of lipoic PAA (compared to the available surface atoms of AuNPs 32 ) was reacted with tannic acid-stabilized (referred to here as 'native') AuNPs (zeta potential, z ¼ À24.4 mV AE 4.3 mV, hydrodynamic diameter, D H ¼ 10.4 nm AE 1.9 nm) and stirred overnight to yield PAA-modied AuNPs. (All reported uncertainties represent one standard deviation calculated from at least three replicate measurements.) This was followed by dialysis to remove unreacted species (PAA-AuNPs, z ¼ À64.7 mV AE 5.4 mV, D H ¼ 25.1 nm AE 3.9 nm in Fig. 1A Indeed, during the Pt II -conjugation reaction, only PAA-AuNPs exhibited the characteristic SPR peak wavelength at 520 nm without any spectral changes. Both native AuNPs and lipoicconjugated AuNPs exhibited a signicant red-shi in their SPR spectra (Fig. 2B ) due to the ion-mediated particle aggregation. The results conrm that the surface-bound PAA chains provide essential strong electrostatic repulsion and steric hindrance to ensure the AuNPs stability on the addition of Pt II ions.
Furthermore, the colloidal stability of Pt II -AuNPs was maintained even under high ionic strength in cell culture media (Eagle's Minimum Essential Medium), with no change in the SPR band (Fig. 2B) . Formation of nanoparticle aggregates is known to signicantly impact the cellular uptake properties.
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Such an enhanced colloidal stability of the Pt II -AuNP formulation (i.e., containing lipoic PAA) is critical for subsequent in vitro studies. Note that massive aggregation of AuNPs was observed when U > 2500, due to interparticle cross-linking 9 mediated by excessive Pt II ions (Table S2 and Fig. S2B in the ESI †).
Given the apparent stable formation of Pt II -AuNPs, as indicated by the characteristic SPR band, and with a desire to further elucidate the binding mechanism of Pt II on lipoic-PAAfunctionalized AuNPs, we utilized attenuated total reectance-Fourier transform infrared (ATR-FTIR) spectroscopy and X-ray photoelectron spectroscopy (XPS). Compared to the conventional FTIR method, the evanescent waves present in the ATR element allows for much greater sensitivity to surface-bound species 36 ( Fig. 3A, le inset) . As shown in Fig. 3A (Fig. 3A, right inset) , leading to size contraction of Pt II -AuNPs as shown in Fig. 1A . Indeed, such bidentate bridging cisplatin-acetate compounds are readily formed with their crystal structure being rmly resolved. 41 Note that the ratio of Pt II to AuNP measured by XPS is about six times greater than the U value in the actual formulation. As the penetration depth of the X-rays was only z10 nm, there was greater sensitivity to the Pt II ions located on the top layer than the Au surface beneath. Details of the XPS analysis are described in the ESI. † Auger-mediated secondary electrons gure prominently for radiation therapy, as discussed previously. To evaluate the performance of our Pt II -AuNPs as an Auger-emitting adjuvant agent, we monitored the secondary electron emission using non-monochromated Bremsstrahlung radiation, a virtual X-ray source for external radiation. As shown in Fig. 4 , Auger electron peaks from both Au and Pt II are indeed observed in the kinetic energy spectrum. The results clearly correspond closely to the Auger lines of each element, and are consistent with their Auger parameters 40 (Table S1 in the ESI †). Although the peak intensities are not sufficiently great due to the low relative sensitivity factor of Auger emission, a single photoelectron emission event can trigger the emission of numerous secondary electrons from the outer shells in high-z elements such as Au and Pt II . Our results provide a proof of concept for the potential as an adjuvant agent for radiation therapy.
In addition to radiation-mediated Auger lines, the in vitro chemotherapeutic potency of Pt II -AuNPs was also evaluated with MCF-7 breast cancer and SKOV-3 ovarian cancer cell lines, both of which were known to be partially resistant to cisplatin (Fig. 5) . Aer 48 h and 72 h treatments using both cell lines, subsequently leading to the triggered drug-release in acidic endosomal environments. -AuNP as an X-ray absorbing adjuvant agent for chemo-radiation cancer therapy. As such, the Pt II -AuNP-mediated therapeutic synergy in concurrent chemo-radiation will be evaluated in due course.
